Form 4 for VRTX Vertex Pharmaceuticals
Accepted 2023-06-20 00:00:00 ET · period of report 2023-06-15 · accession 0001209191-23-038343 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-06-20 | 2023-06-15 | VRTX | Arbuckle Stuart A | EVP, COO | M - OptEx | $187.53 | +8,603 | 65.2K | +15% | +$1.61M |
| D | 2023-06-20 | 2023-06-15 | VRTX | Arbuckle Stuart A | EVP, COO | S - Sale+OE | $349.00 | -8,603 | 56.6K | -13% | -$3.00M |
| D | 2023-06-20 | 2023-06-15 | VRTX | Arbuckle Stuart A | EVP, COO | M - OptEx | $0.00 | -8,603 | 8,603 | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-15 | M | A | 8,603 | $187.53 | 65,159 | D | — | — | |
| 2 | Common | Common Stock | 2023-06-15 | S | D | 8,603 | $349.00 | 56,556 | D | — | — | (F3) Open market sales reported on this line occurred at a weighted average price of $349.00 (range $349.00 to $349.02). (F2) Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-06-15 | M | D | 8,603 | $0.00 | 8,603 | D | $187.53 · — to 2029-02-05 | 8,603 Common Stock | (F4) Fully vested. |